216 related articles for article (PubMed ID: 29758126)
1. Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.
Stagaard R; Flick MJ; Bojko B; Goryński K; Goryńska PZ; Ley CD; Olsen LH; Knudsen T
J Thromb Haemost; 2018 Jul; 16(7):1369-1382. PubMed ID: 29758126
[TBL] [Abstract][Full Text] [Related]
2. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A.
Hvas AM; Sørensen HT; Norengaard L; Christiansen K; Ingerslev J; Sørensen B
J Thromb Haemost; 2007 Dec; 5(12):2408-14. PubMed ID: 18034766
[TBL] [Abstract][Full Text] [Related]
3. In vivo effect of rFVIII and rFVIIa in hemophilia A rats evaluated by the Tail Vein Transection Bleeding Model.
Stagaard R; Øvlisen GO; Klæbel JH; Danielsen D; Lund A; Elm T; Ley CD
J Thromb Haemost; 2023 May; 21(5):1189-1199. PubMed ID: 36696187
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
5. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
[TBL] [Abstract][Full Text] [Related]
6. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
7. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A.
Strilchuk AW; Hur WS; Batty P; Sang Y; Abrahams SR; Yong ASM; Leung J; Silva LM; Schroeder JA; Nesbitt K; de Laat B; Moutsopoulos NM; Bugge TH; Shi Q; Cullis PR; Merricks EP; Wolberg AS; Flick MJ; Lillicrap D; Nichols TC; Kastrup CJ
Sci Transl Med; 2024 Feb; 16(735):eadh0027. PubMed ID: 38381848
[TBL] [Abstract][Full Text] [Related]
9. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.
Lisman T; de Groot PG; Lambert T; Røjkjaer R; Persson E
J Thromb Haemost; 2003 Oct; 1(10):2175-8. PubMed ID: 14521601
[TBL] [Abstract][Full Text] [Related]
10. The inhibiting effect of factor XIII on hyperfibrinolysis.
Theusinger OM
Anesth Analg; 2012 Jun; 114(6):1149-50. PubMed ID: 22615440
[No Abstract] [Full Text] [Related]
11. Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Barrett CD; Moore HB; Kong YW; Chapman MP; Sriram G; Lim D; Moore EE; Yaffe MB
J Trauma Acute Care Surg; 2019 Jan; 86(1):101-107. PubMed ID: 30575685
[TBL] [Abstract][Full Text] [Related]
12. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice.
Ovlisen K; Kristensen AT; Valentino LA; Hakobyan N; Ingerslev J; Tranholm M
J Thromb Haemost; 2008 Jun; 6(6):969-75. PubMed ID: 18363814
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis.
Draxler DF; Daglas M; Fernando A; Hanafi G; McCutcheon F; Ho H; Galle A; Gregory J; Larsson P; Keragala C; Wright DK; Tavancheh E; Au AE; Niego B; Wilson K; Plebanski M; Sashindranath M; Medcalf RL
J Thromb Haemost; 2019 Dec; 17(12):2174-2187. PubMed ID: 31393041
[TBL] [Abstract][Full Text] [Related]
14. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Rea CJ; Foley JH; Bevan DH; Sørensen B
Ann Hematol; 2014 Apr; 93(4):683-92. PubMed ID: 24193375
[TBL] [Abstract][Full Text] [Related]
15. Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.
Stagaard R; Ley CD; Almholt K; Olsen LH; Knudsen T; Flick MJ
Blood Adv; 2018 Nov; 2(22):3126-3136. PubMed ID: 30459211
[TBL] [Abstract][Full Text] [Related]
16. Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery.
Miszta A; Ahmadzia HK; Luban NLC; Li S; Guo D; Holle LA; Berger JS; James AH; Gobburu JVS; van den Anker J; de Laat B; Wolberg AS
J Thromb Haemost; 2021 Jan; 19(1):221-232. PubMed ID: 33001565
[TBL] [Abstract][Full Text] [Related]
17. Increased urokinase and consumption of α
Longstaff C; Locke M
J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
[TBL] [Abstract][Full Text] [Related]
18. An in vitro study of the effects of t-PA and tranexamic acid on whole blood coagulation and fibrinolysis.
Godier A; Parmar K; Manandhar K; Hunt BJ
J Clin Pathol; 2017 Feb; 70(2):154-161. PubMed ID: 27445340
[TBL] [Abstract][Full Text] [Related]
19. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Lisman T; Mosnier LO; Lambert T; Mauser-Bunschoten EP; Meijers JC; Nieuwenhuis HK; de Groot PG
Blood; 2002 Jan; 99(1):175-9. PubMed ID: 11756168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
